yyhwin
2021-11-09
Hi
Biohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
2
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":847003256,"tweetId":"847003256","gmtCreate":1636465586396,"gmtModify":1636466390507,"author":{"id":3581931076615563,"authorId":3581931076615563,"authorIdStr":"3581931076615563","name":"yyhwin","avatar":"https://static.tigerbbs.com/78727032603c2751ac0b6b6cfb678920","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hi</p></body></html>","htmlText":"<html><head></head><body><p>Hi</p></body></html>","text":"Hi","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847003256","repostId":1106779574,"repostType":4,"repost":{"id":"1106779574","pubTimestamp":1636465348,"share":"https://www.laohu8.com/m/news/1106779574?lang=&edition=full","pubTime":"2021-11-09 21:42","market":"us","language":"en","title":"Biohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1106779574","media":"Reuters","summary":"Nov 9 (Reuters) - Pfizer Inc will acquire overseas marketing rights to two migraine drugs from Bioha","content":"<p>Nov 9 (Reuters) - Pfizer Inc will acquire overseas marketing rights to two migraine drugs from Biohaven Pharmaceutical Holding Co for up to $1.24 billion, the companies said on Tuesday.</p>\n<p>The deal includes an upfront payment of $500 million for the rights to Biohaven's rimegepant and zavegepant. The payment consists of $150 million in cash and $350 million for the purchase of Biohaven equity at a 25% market premium.</p>\n<p>Biohaven will also be able to fetch another $740 million in milestone payments and receive double-digit royalties on the drugs' overseas net sales from Pfizer.</p>\n<p>Rimegepant, marketed as Nurtec ODT in the United States, has been approved for the acute treatment of migraine attacks and the prevention of episodic migraine in adults.</p>\n<p>The drug brought in sales of about $136 million in the quarter ended Sept. 30, a 46% jump over the previous three months.</p>\n<p>Biohaven has applied for rimegepant's approval with the European Medicines Agency and several other regulatory authorities outside the United States.</p>\n<p>Zavegepant is being studied as an intranasal and a soft-gel formulation in late-stage clinical trials for migraine.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 21:42 GMT+8 <a href=https://finance.yahoo.com/news/1-biohaven-pfizer-enter-1-133143671.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 9 (Reuters) - Pfizer Inc will acquire overseas marketing rights to two migraine drugs from Biohaven Pharmaceutical Holding Co for up to $1.24 billion, the companies said on Tuesday.\nThe deal ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-biohaven-pfizer-enter-1-133143671.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-biohaven-pfizer-enter-1-133143671.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106779574","content_text":"Nov 9 (Reuters) - Pfizer Inc will acquire overseas marketing rights to two migraine drugs from Biohaven Pharmaceutical Holding Co for up to $1.24 billion, the companies said on Tuesday.\nThe deal includes an upfront payment of $500 million for the rights to Biohaven's rimegepant and zavegepant. The payment consists of $150 million in cash and $350 million for the purchase of Biohaven equity at a 25% market premium.\nBiohaven will also be able to fetch another $740 million in milestone payments and receive double-digit royalties on the drugs' overseas net sales from Pfizer.\nRimegepant, marketed as Nurtec ODT in the United States, has been approved for the acute treatment of migraine attacks and the prevention of episodic migraine in adults.\nThe drug brought in sales of about $136 million in the quarter ended Sept. 30, a 46% jump over the previous three months.\nBiohaven has applied for rimegepant's approval with the European Medicines Agency and several other regulatory authorities outside the United States.\nZavegepant is being studied as an intranasal and a soft-gel formulation in late-stage clinical trials for migraine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":7,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/847003256"}
精彩评论